Cardiol Therapeutics
CRDL
26 hedge funds and large institutions have $4.88M invested in Cardiol Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.86% less ownership
Funds ownership: 8.56% → 7.69% (-0.86%)
4% less funds holding
Funds holding: 27 → 26 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
30% less capital invested
Capital invested by funds: $6.98M → $4.88M (-$2.1M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$42.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$27.2K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$18K |
| 4 |
Morgan Stanley
New York
|
+$15.4K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$592K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$82.2K |
| 3 |
Two Sigma Advisers
New York
|
-$32.4K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$21.6K |
| 5 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$20K |
CRDL Hedge Fund Activity: Q3 2022 in Review
26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q3 2022, worth a combined $4.88M — down 30% from $6.98M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRDL and 4 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $42.1K. The largest seller was Mirae Asset Global Investments, cutting an estimated $592K.
- 26 institutional investors held Cardiol Therapeutics (CRDL) as of Q3 2022, down from 27 in Q2 2022.
- Funds reported $4.88M of Cardiol Therapeutics stock for Q3 2022, down 30% quarter-over-quarter.
- 4 funds opened new Cardiol Therapeutics positions in Q3 2022 and 5 closed out, a net change of -1 holder.
- The largest Cardiol Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $42.1K added.
- The largest Cardiol Therapeutics seller in Q3 2022 was Mirae Asset Global Investments, an estimated $592K sold.
Based on aggregated 13F filings for Q3 2022.